This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

I believe he will say very little about MMG.

Your right nothing on MMG,thats a sign that hes getting worried.

cheers GF.

Or he's out of it.

I saw from his psots on advfn that he went long for a while and had banked some cash, that was quite a few days ago.

I read between the lines that he would close his short.

Of course he leaves his phone number all over the place, so it will be easy for soemone to confirm.

All gone extremely quiet on here considering the optimism for this week!!
Lets hope that the good news see's this recover back to 300p.
Excellent posts from gf and Mitzy again last week.

Yes it could be a big week ahead, I see Mike Walters late friday had something to say on his site, Looks good.....................


Patent Power
22/4/2005

Medical Marketing has added more value by winning new patents.
[Read more

cheers Gf.

For those who have not received an invite for the R&D presentation you can follow proceedings via a live web cast which includes slides at the following address:

http://mediaserve.buchanan.uk.com

The link for MMI should appear next Tuesday.


http://mediaserve.buchanan.uk.com

cheers GF.

Hi GF.
I think you mean tomorrow, Tuesday 26th.
Cheers.

Sorry yes I do. Cheers Porky.

Seems to be a big line of sells, any adverse news out?

looked again GF, you are really right because next tuesday is tomorrow.
At first glance it looked like you had made a mistake.
Sorry for jumping the gun.
Noticed the sales but the bid price has just risen.
Hope everthing goes as expected.
Cheers.

Ah yes buyers coming back in, coming back in strongly, NICE.

cheers GF.

From the other place. The meeting is at 11.30 for 11.45

BennytheBall - 25 Apr'05 - 08:57 - 5217 of 5217


In relation to valuation, I wonder if we've lost sight of an important aspect of MMG's business model.

Have a look at slide 4 of the presentation from the last AGM, here: http://www.bendavidson.co.uk/mmg.ppt

It shows the way phase II clinical trials add the greatest value of any stage within the development pipeline. The text that goes with that slide (see the link to 'chairman's report' above) is:
"If MMI is able to license on its blockbusters at the end of stage II, shareholders should not have to wait until products are actually marketed to see a highly significant value-added step."

The implication, I've always understood, is that MMG wants to concentrate on getting drugs to this stage and then passing on the risk in a way that maximises shareholder value; i.e. selling a suite of successful phase II ruthenium products, maybe via a sale of Oncosense as a whole to a big pharma, is more in keeping with the business plan than taking each of the drugs through to market itself.

If I am right, the length of time to market and to the growth of large revenue streams from the drugs is not critical. It's the number of possible blockbusters in the portfolio and the extent to which they can be taken comprehensively through phase II trials, in a market where big pharma have a paucity of products coming through themselves, that is the most significant clue to likey market capitalisation going forward.

That might also explain the perceived delay in Ruthenium announcements - the fact that more products than expected appear to be optimum candidates for phase II trials could well mean that MMI are aiming at a cluster of trials starting at the same time to optimise the value when the big pharma waiting in the wings start bidding to buy the lot...

MS

I have bought in this morning ahead of Tuesdays meeting I expect 250p if the news is as good as say it is..especially if there is talk of a tie-up sometime this year.

It's going up, looking good to me.

MS

I always thought that was the game plan, develop the drugs early on in trials and flog them to a big pharma for further development. The Bears would have you beleive that this is not the case but I can rember Best stating this a few years back now.

cheers GF.

Thats where the shorters got it wrong gf as DB will sell to a big pharma at the end of phase 2 rather than phase 3 and that could be sooner than most people think.

Any idea how soon mitzy. Are we talking say 2-3 months or longer. Any guidance would be appreciated.

MS

mickey:reckon we will have to wait till tommorow but would have thought at least 6 months.

OK thanks for that mitzy.

MS

From the other place. Some good postings today. Makes a change, although the guys that post on MMG are good and sensible.

469514 - 25 Apr'05 - 09:35 - 5222 of 5223


Michael Walters says in his site that there will certainly not be any price sensitive new information issued in tomorrow's presentation, and he does seem to to talk to David Best a lot. So we shouldn't build up expectations. However the shares may still get propelled upwards from a wider media knowledge about what is going on.

It is very clear to me, from a close study of the Walter's articles and some emails from Mr Best, that Genvax could be a huge breakthrough in cancer treatment. And yet the press do not seem to have picked up even a whiff of this excitement.

There is only a relatively small number of people aware of the superb potential here and it demonstrates to me, again, the value of sensible buletin board discussion that we often get on here. The presentations will inevitably have to be cautious at this stage but if the press can get a sense of Best's enthusiasm and see through to the underlying message in the test results then we could see quite a dramatic re-rating of the shares.

At first sight, Benny's predictions do look somewhat extravagant, but if everything goes well I think he could be right.

Nothing can be certain in this sector of investment and there have indeed been numerous disappointments with late stage drug trials in the past. "They said the same thing about British Biotech" is often heard from the sceptics. But one day a company will hit the jackpot and imho, MMG looks like one of the likliest candidates to do just this.

Xylos

MS

If anyone's shorting these they are going to get stuffed.

MS